Sign up for free insights newsletter
MD

Madrigal Pharmaceuticals Inc

MDGLUnited States

Need professional-grade analysis? Visit stockanalysis.com

$445.04
+0.88%
End of day
Market Cap

$10.27B

P/E Ratio

N/A

Employees

N/A

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino20.161.21-1.910.311.081.57
Calmar4.93-2.400.301.010.64
Sharpe3.580.78-1.690.200.670.28
Omega4.631.200.551.081.151.25
Martin10.60-3.450.612.301.77
Ulcer0.112.0920.4314.2812.8812.47

Madrigal Pharmaceuticals Inc (MDGL) Price Performance

Madrigal Pharmaceuticals Inc (MDGL) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $445.04, up 0.88% from the previous close.

Over the past year, MDGL has traded between a low of $267.56 and a high of $602.83. The stock has gained 33.3% over this period. It is currently 26.2% below its 52-week high.

Madrigal Pharmaceuticals Inc has a market capitalization of $10.27B.

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$958.40M
EBITDA
$-298,591,008
Profit Margin
-30.08%
EPS (TTM)
-12.85
Book Value
26.39

Technical Indicators

52 Week High
$615.00
52 Week Low
$265.00
50 Day MA
$482.29
200 Day MA
$433.17
Beta
-0.96

Valuation

Trailing P/E
N/A
Forward P/E
34.99
Price/Sales
10.72
Price/Book
16.97
Enterprise Value
$9.63B